Peptide FDA Approval Tracker
A sourced, point-in-time map of where every major peptide stands with the FDA (approved drug, clinical-trial candidate, or research chemical), plus the compounding rules that keep changing.
Still logging injections in your Notes app?
A notes thread can't show a missed day at a glance, because it's a list, not a calendar. A printed log can. Your compounds and dates filled in: injection log, weekly schedule, dated calendar. Free to build and preview; $5/month to unlock printing.
How It Works
A prescription drug the FDA has reviewed and cleared for a specific use. Has an application number in Drugs@FDA. Example: semaglutide (Wegovy).
Under active study in registered human trials but not yet approved. Not legally available by prescription. Example: retatrutide (Phase 3).
Sold "for research use only," with no FDA approval for the marketed use, and not among the peptides the FDA took to its compounding advisory committee in July 2026. Example: most SARMs, and MK-677, which also sits on FDA's current Category 2 list.
Not approved and not on the FDA's 503A bulks list, so not eligible for 503A pharmacy compounding (FDA's 503A rules), but under active FDA review for that list: the FDA took it to its Pharmacy Compounding Advisory Committee in July 2026 (meeting agenda). That review is what earns this badge; each row notes any Category 2 history separately. Example: BPC-157, placed in 503A Category 2 on September 29, 2023 (FDA list as archived in 2024); FDA's current list shows that nomination as withdrawn by its nominators, and the FDA still brought BPC-157 to the July 2026 committee.
What the Data Shows
Peptide FDA Approval Status
FDA-approved drugs vs. compounds still in trials vs. research chemicals, with the FDA application number or ClinicalTrials.gov trial behind every approved and in-trial status.
| Compound | Status | Indication / Note | Source |
|---|---|---|---|
| Semaglutide Ozempic · Wegovy · Rybelsus |
✅ Approved | Type 2 diabetes & chronic weight management | FDA NDA 209637 (Ozempic) / 215256 (Wegovy) / 213051 (Rybelsus) (Novo Nordisk) |
| Tirzepatide Mounjaro · Zepbound |
✅ Approved | Type 2 diabetes & obesity | FDA NDA 215866 / 217806 (Eli Lilly) |
| Liraglutide Victoza · Saxenda |
✅ Approved | Type 2 diabetes & obesity (generics now available) | FDA NDA 022341 (Victoza) / 206321 (Saxenda) (Novo Nordisk); generic ANDA 215503 (Hikma) |
| Dulaglutide Trulicity |
✅ Approved | Type 2 diabetes | FDA BLA 125469 (Eli Lilly) |
| Exenatide Byetta · Bydureon · Bydureon BCISE |
✅ Approved | Type 2 diabetes | FDA NDA 021773 / 021919 (Byetta); NDA 022200 (Bydureon) / 209210 (Bydureon BCISE), both listed as discontinued |
| Bremelanotide PT-141 · Vyleesi |
✅ Approved | Hypoactive sexual desire disorder (women) | FDA NDA 210557 |
| Setmelanotide Imcivree |
✅ Approved | Rare genetic (MC4R-pathway) obesity | FDA NDA 213793 (Rhythm) |
| Tesamorelin Egrifta |
✅ Approved | HIV-associated lipodystrophy | FDA BLA 022505 (Theratechnologies) |
| Orforglipron Foundayo (oral, non-peptide GLP-1) |
✅ Approved | Chronic weight management (approved April 1, 2026) | FDA NDA 220934 (Eli Lilly) |
| Retatrutide LY3437943 · "triple-G" |
🔬 Phase 3 | Obesity / metabolic (Lilly TRIUMPH program) | ClinicalTrials.gov NCT06297603 (not yet approved) |
| Survodutide BI 456906 |
🔬 Phase 3 | Obesity & MASH | ClinicalTrials.gov NCT06309992 (Boehringer / Zealand) |
| Cagrilintide part of CagriSema |
🔬 Phase 3 | Obesity (paired with semaglutide) | ClinicalTrials.gov NCT07220759 (Novo Nordisk) |
| Mazdutide IBI362 · LY3305677 |
🔬 Phase 3 | Obesity (approved in China June 2025 per Innovent; not FDA-approved) | ClinicalTrials.gov NCT07469800 (Innovent) |
| BPC-157 Body Protection Compound-157 |
⚠️ Restricted | Not approved. Placed in 503A Category 2 on Sep 29, 2023 (FDA's current list shows that Category 2 nomination as withdrawn); an FDA advisory committee (PCAC, Jul 23, 2026) voted to recommend it for the 503A list: rulemaking pending, not yet legal to compound. | FDA Category 2 list (2024 archive); early trial NCT07437547 (Phase 2); PCAC recommendation Jul 2026 |
| Thymosin beta-4 TB-500 |
⚠️ Restricted | Not approved. Formerly in FDA Category 2 (FDA's current list shows that nomination as withdrawn); an FDA advisory committee (PCAC, Jul 23, 2026) voted to recommend TB-500 for the 503A list: rulemaking pending, not yet legal to compound. | FDA 503A bulk-substance review; PCAC recommendation Jul 2026 |
| CJC-1295 / Ipamorelin GH secretagogues |
⚗️ Research chem | Not approved. Both named in a 2020 FDA warning letter to a 503A compounder as ineligible bulk substances. FDA's current list shows ipamorelin acetate in 503B Category 2 and CJC-1295 as nominated but withdrawn. | No FDA approval on record; FDA warning letter to Tailor Made Compounding (Apr 1, 2020) |
| MK-677 Ibutamoren |
⚗️ Research chem | Investigational GH secretagogue, never FDA approved. FDA's current Category 2 list includes ibutamoren mesylate (503A and 503B). Unlike BPC-157, it was not on the agenda of the July 2026 PCAC meeting, so it was not part of that vote and remains in Category 2. | No FDA approval on record |
| SARMs Ostarine · RAD-140 · LGD-4033 … |
⚗️ Research chem | None FDA approved; the FDA warns consumers that SARM bodybuilding products are unapproved drugs | FDA consumer warning (Fraudulent Products) |
| Melanotan II MT-II |
⚗️ Research chem | Not approved for any use. Placed in 503A Category 2 on Sep 29, 2023 (2024 archive); FDA's current list shows that nomination as withdrawn by its nominators. | No FDA approval on record |
| Epitalon Epithalon |
⚠️ Restricted | Not approved as a drug. Formerly in FDA Category 2 (FDA's current list shows that nomination as withdrawn); PCAC voted (Jul 24, 2026) to recommend Epitalon for the 503A compounding list: rulemaking pending, not yet legal. | No FDA drug approval; PCAC recommendation Jul 2026 |
Sources: FDA Drugs@FDA (drugsfda) application records and U.S. National Library of Medicine ClinicalTrials.gov, verified July 8, 2026; orforglipron and exenatide application records re-checked against openFDA October 25, 2026; semaglutide and liraglutide application numbers re-checked against openFDA November 20, 2026; FDA Category 2 entries checked against FDA's list on November 20, 2026. "Research chemical" = sold for laboratory research only, with no FDA approval for the listed use. "Restricted" = on the FDA's July 2026 PCAC agenda for the 503A bulks list; Category 2 status is noted per row and does not set the badge.
The FDA's Pharmacy Compounding Advisory Committee voted to recommend six of seven nominated peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax) while rejecting DSIP / emideltide (FDA meeting page; NCPA vote summary). This is a non-binding recommendation, not FDA approval and not legalization: per NCPA, the HHS Secretary must still formally approve the additions, and pharmacies may not compound them until the final rule is in place. The timing is uncertain. As of November 20, 2026, a Federal Register search of FDA documents published July 1 to November 20, 2026 (run November 20, 2026) found no proposed or final rule adding them to the 503A bulks list, so the status badges above have not changed.
Full breakdown: the FDA July 2026 peptide vote →The Compounding & Policy Timeline
Why "you could get it last year" doesn't mean "you can get it legally today." The rules around compounded peptides have moved repeatedly.
The FDA approves Vyleesi (2019), Imcivree (2020), Wegovy (2021), Mounjaro (2022) and Zepbound (2023), per their Drugs@FDA application records.
On September 29, 2023 the FDA placed several popular peptides, including BPC-157, TB-500 and Epitalon, in 503A Category 2 (FDA list, 2024 archive), citing potential safety risks and limited safety data. Category 2 takes a substance outside the FDA's interim policy of not acting against compounders, and the FDA says it "would consider taking action" against a compounder using one under its general enforcement policies (FDA 503A page). FDA's current list shows those nominations as withdrawn by the nominators.
The FDA declared the tirzepatide shortage resolved (December 2024) and the semaglutide shortage resolved (February 2025). Compounding near-copies of these drugs had depended on their shortage-list status, so the FDA set 2025 end dates for its enforcement discretion for 503A pharmacies and 503B outsourcing facilities (FDA compounder update, 2025 archive).
The Senate confirmed Robert F. Kennedy Jr. as HHS Secretary on February 13, 2025 (roll call 52); NCPA reports he has expressed support for compounding peptides. Outsourcing Facilities Association lawsuits against the GLP-1 shortage decisions were denied preliminary injunctions in March and April 2025, per the FDA.
The FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax for the 503A bulks list (rejecting DSIP / emideltide). This is a non-binding recommendation, not approval: per NCPA, the HHS Secretary must still approve the additions and pharmacies may not compound them until final rulemaking is in place. As of , a Federal Register search of FDA documents published July 1 to November 20, 2026 (run November 20, 2026) found no proposed or final rule adding them to the 503A bulks list. Treat any "it's now legal" claim as false until that final rule issues. See the full vote breakdown →
Key Takeaways
- Nine drugs on this list are fully FDA-approved, each with a verifiable Drugs@FDA application number: eight peptides — the GLP-1s (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide) plus bremelanotide, setmelanotide, and tesamorelin — and orforglipron, an oral non-peptide GLP-1 pill approved on April 1, 2026 as Foundayo (NDA 220934).
- The most-hyped weight-loss peptides that are NOT yet approved (retatrutide, survodutide, cagrilintide, mazdutide) are in Phase 3 trials, with real ClinicalTrials.gov registrations.
- BPC-157 is not FDA-approved. The FDA placed it in 503A Category 2 in September 2023, which took it outside the agency's interim policy of not acting against compounders; FDA's current list shows that Category 2 nomination as withdrawn.
- Compounding near-copies of semaglutide and tirzepatide depended largely on their shortage-list status; the FDA declared those shortages resolved (December 2024 and February 2025) and ended its enforcement discretion in 2025.
- SARMs, MK-677, melanotan II, and CJC-1295/ipamorelin have no FDA approval for the uses they are marketed for.
- Whether, and when, the July 2026 PCAC recommendation becomes a binding rule; as of November 20, 2026 no proposed or final rule on the 503A bulks list had appeared in the Federal Register, so the six peptides' compounding status has not changed.
- Exact, current enforcement dates and state-by-state pharmacy-board interpretation of the compounding rules, which can shift with new FDA notices, state rules and court cases.
- Whether Phase 3 trial peptides (retatrutide, survodutide, etc.) will ultimately be approved, and for which indications. Trials can still fail.
- The long-term safety profile of compounds still in trials or sold as research chemicals: for several of them, FDA's Category 2 entries say the agency lacks sufficient information to know whether they would cause harm in humans.
Frequently Asked Questions
Is BPC-157 FDA approved?
No. BPC-157 is not approved by the FDA for any use. In its 2023 review of bulk drug substances for pharmacy compounding, the FDA placed BPC-157 in Category 2, citing potential safety risks and limited safety data, which took it outside the FDA's interim policy of not acting against compounders; FDA's current list shows that Category 2 nomination as withdrawn. An early-stage human trial (NCT07437547) is recruiting, but that is a long way from approval.
Is retatrutide FDA approved?
No, not yet. Retatrutide (LY3437943) is in Phase 3 clinical trials as part of Eli Lilly's TRIUMPH program (for example, NCT06297603). It is not available by prescription and cannot be legally sold as a drug until and unless the FDA approves it.
Which weight-loss peptides are actually FDA approved?
For weight management specifically: semaglutide (Wegovy), tirzepatide (Zepbound), liraglutide (Saxenda), and setmelanotide (Imcivree, for rare genetic obesity). The GLP-1s are also approved for type 2 diabetes under other brand names. Orforglipron (Foundayo), an oral non-peptide GLP-1 pill, was approved for chronic weight management on April 1, 2026. Retatrutide, survodutide, cagrilintide, and mazdutide are still in trials.
Are compounded semaglutide and tirzepatide still legal?
Their legal basis narrowed sharply. Large-scale compounding of these drugs was permitted mainly because they were on the FDA shortage list. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025, and ended its enforcement discretion for compounders in 2025. Industry lawsuits (Outsourcing Facilities Association v. FDA) were denied preliminary injunctions in 2025. Confirm current rules with a licensed pharmacist.
Has the new administration changed peptide regulation?
There has been movement, but not yet a change in legal status. On July 23–24, 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) for the 503A compounding list and rejected DSIP/emideltide. That is a non-binding recommendation, not approval: as of November 20, 2026 no proposed or final rule adding them to the 503A bulks list had appeared in the Federal Register, so none of the six is yet legal to compound under 503A. Treat any "it's approved / now legal" claim as false until the FDA completes formal rulemaking.
Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify). HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links support HighPeptides at no extra cost.
67-page guide: protocols, dosing, sourcing. Everything in one place.
Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) The Peptide Buyer’s Playbook ($19) All ebooks & guides →Educational purposes only. Not medical advice.
Regulatory status changes frequently and varies by jurisdiction. This page is a point-in-time snapshot as of the stated update date. Always verify current FDA status and consult a licensed clinician or pharmacist before making any decision.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.